echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The mechanism of cancer recurrence revealed that cancer cells may enter a dormant state and escape chemotherapy!

    The mechanism of cancer recurrence revealed that cancer cells may enter a dormant state and escape chemotherapy!

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Acute myeloid leukemia (AML) is the deadliest of all blood cancers, with 3 out of 4 patients dying within 5 years.


    Most patients have recurrence of AML after chemotherapy, which indicates that the disease cannot be cured.


    Stem Cell Immunity

    A photomicrograph of a bone marrow aspirate from a patient with leukocytosis, showing the original cells of acute myeloid leukemia.


    A new study published by Will-Cornell Medical’s scientists in the American Cancer Research Association’s Journal of Cancer Discovery shows that cancer cells can escape chemotherapy by entering a state similar to aging.


    Cancer cells can evade chemotherapy by entering a state similar to aging, a type of "active hibernation" that allows them to resist the stress caused by aggressive treatments designed to destroy cancer cells.


    The research was conducted in organisms and mouse models made from patients’ acute myeloid leukemia (AML) tumor samples.


    "Acute myeloid leukemia can enter remission through chemotherapy, but it almost always recurs.


    For many years, cancer researchers have been studying how tumors recur after seemingly eliminated by chemotherapy.


    In the study, the researchers found that when AML cells were exposed to chemotherapy, some of the cells entered a hibernation state, or aging state, while at the same time, the cells were in a state very similar to inflammation.


    Induction chemotherapy-induced senescence

    "These characteristics are also common in developing embryos, where their growth is suspended due to lack of nutrients.


    Further studies have shown that this inflammatory senescence state is induced by a protein called ATR, which suggests that blocking ATR may be a way to prevent cancer cells from adopting this state.


    This inflammatory senescence state is induced by a protein called ATR, which suggests that blocking ATR may be a way to prevent cancer cells from adopting this state.


    diagnosis

    Overall, studies have shown that primary AML cells enter an senescence-like phenotype after chemotherapy in vitro and in vivo.


    Primary AML cells enter the senescence-like phenotype after chemotherapy in vitro and in vivo.


    The effect of aging is not only important for AML, but also for the recurrence of breast , prostate and gastrointestinal cancer.


    The research team stated that timing is critical before the problem can be studied in patients, so there is still a lot of work to be done in the laboratory.


    Original source:

    aacrjournals.
    org/content/early/2021/01/25/2159-8290.
    CD-20-1375" target="_blank" rel="noopener">Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence .
    Cancer Discov January 26 2021 DOI: 10.
    1158/2159-8290.
    CD-20-1375

    aacrjournals.
    org/content/early/2021/01/25/2159-8290.
    CD-20-1375" target="_blank" rel="noopener">Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.